XXB750 NPR1 Agonist — Heart Failure Safety Signal
TL;DR
XXB750 (Novo Nordisk) was a human monoclonal antibody designed as an NPR1 (natriuretic peptide receptor 1) agonist for heart failure. A Phase 2 RCT (NCT06142383, Nature Medicine, PMID 41912806) was terminated early due to a severe cardiac safety signal: 25% of XXB750 patients experienced death or worsening heart failure vs 0% placebo. NT-proBNP paradoxically increased (ratio 1.34) and cGMP paradoxically decreased (ratio 0.77) — opposite of the intended NPR1 agonist effect. The drug appeared to function as a functional antagonist of endogenous natriuretic peptides in HF patients. The program was discontinued.
Verdict: A landmark case of a rationally designed drug producing paradoxical reverse pharmacology in its intended disease population. No patients should currently be on XXB750.
Why it matters for Vitals
- Cardiovascular safety case study: A drug designed to mimic beneficial natriuretic peptide effects in HF produced the opposite — raising NT-proBNP and triggering HF decompensation
- No current patient relevance: Program discontinued; no active patients on XXB750
- Relevant for vericiguat/riociguat context: XXB750 failure does NOT implicate the cGMP pathway in HF — vericiguat works downstream at sGC and has proven benefit (VICTORIA trial)
- Biomarker interpretation: When targeting NPR1, NT-proBNP changes can be paradoxical — can’t be used as a simple efficacy biomarker
Key facts
- Mechanism: Human monoclonal antibody NPR1 agonist (intended); functional antagonist in HF patients (actual)
- Trial: Phase 2 RCT, NCT06142383, HFrEF (LVEF <50%), N=136
- Doses: 60 mg XXB750 (n=26), 120 mg XXB750 (n=55), placebo (n=29), open-label sacubitril/valsartan (n=25)
- Duration: 16-week primary endpoint; trial terminated early by DMC
- NT-proBNP: Increased ratio 1.34 (95% CI 1.07-1.66) in pooled XXB750 arms — opposite of expected
- cGMP: Decreased ratio 0.77 (95% CI 0.65-0.91) — opposite of expected
- Death/worsening HF: 25% XXB750 vs 8% sacubitril/valsartan vs 0% placebo
- Safety outcome: Trial terminated early; program discontinued by Novo Nordisk
- Status: Discontinued
Mechanism summary
Intended: XXB750 was designed to activate NPR1 → guanylyl cyclase → cGMP → vasodilation, natriuresis, RAAS inhibition — all theoretically beneficial in HF.
Actual in HF patients: XXB750 paradoxically increased NT-proBNP and decreased cGMP — suggesting it functionally antagonized the natriuretic peptide system. Possible mechanisms: receptor density/shedding in HF, competition with chronically elevated endogenous natriuretic peptides, or antibody-specific receptor dynamics. The mechanistic explanation is not yet published.
Preclinical (Nature 2024, PMID 39261724): XXB750 functioned as an NPR1 agonist in non-HF models. The disease-state reversal is unexplained.
What happened vs what was expected
| Parameter | Expected (NPR1 agonist) | Actual (XXB750 in HF) | Evidence |
|---|---|---|---|
| NT-proBNP | Decrease | Increase (ratio 1.34) | Confirmed |
| cGMP | Increase | Decrease (ratio 0.77) | Confirmed |
| Worsening HF events | Decrease | 25% vs 0% placebo | Confirmed |
Vitals coaching context
- Vericiguat (BAY 1021189): Works downstream at sGC (not NPR1). Has VICTORIA trial benefit in HFrEF. XXB750 failure does not affect vericiguat use.
- Riociguat: For PAH/CTEPH, not HF. No implicated by XXB750.
- Nesiritide: Historical context; recombinant BNP, not NPR1 antibody. Had its own safety issues.
- For patients asking about XXB750: Explain it was discontinued after a safety signal; no patients are on it; no relevance to current HF medications.
- For patients on HF medications asking about safety: The XXB750 case illustrates why Phase 2 safety monitoring is critical — even rationally designed agonists can produce reverse effects in disease states.
Vitals Coaching Summary
What Patients Currently on Sacubitril/Valsartan (Entresto) Should Know
✅ Continue sacubitril/valsartan. The XXB750 trial does not change the evidence base for Entresto. PARADIGM-HF demonstrated a 20% reduction in cardiovascular death or heart failure hospitalization. There is no evidence that sacubitril/valsartan caused harm in the XXB750 trial.
✅ Ensure comprehensive GDMT: Patients on sacubitril/valsartan should also be on an SGLT2 inhibitor (dapagliflozin or empagliflozin), a beta-blocker, and a mineralocorticoid receptor antagonist (spironolactone or eplerenone) to minimize residual risk.
✅ Daily weight monitoring and reporting of symptoms: Sudden weight gain, increasing shortness of breath, or edema should prompt contact with the prescribing clinician.
What Patients on Vericiguat Should Know
✅ Continue vericiguat if prescribed. The XXB750 NPR1 signal does not apply directly to vericiguat, which acts on a different guanylate cyclase isoform (sGC, not pGC/NPR1).
✅ Report symptoms of hypotension (dizziness, fainting) to the prescribing clinician.
What Patients Considering New Heart Failure Therapies Should Know
⚠️ Approach novel NPR1-targeting therapies with extreme caution. The XXB750 failure demonstrates that compelling biological rationale does not guarantee clinical benefit and can cause harm. Any future NPR1-targeting therapy would need to explain the XXB750 failure before it could be considered for clinical use.
What Vitals Should Monitor and Flag
- Any new NPR1 agonist entering clinical development → flag for evidence review
- Any new FDA/EMA communications about the NPR1 pathway or XXB750 → incorporate into this note
- Emerging evidence on the mechanism of harm → update this note when published
Evidence Gaps and Research Agenda
| Gap | Priority | Notes |
|---|---|---|
| Peer-reviewed XXB750 trial publication | Critical | Needed before any stronger claims can be made |
| Mechanism of harm | Critical | Three hypotheses proposed (receptor desensitization, supraphysiologic cGMP toxicity, beta-arrestin bias) — none confirmed |
| Trial population details | High | HFrEF vs HFpEF, LVEF range, NYHA class, baseline characteristics |
| Event timing and dose-dependency | High | Would help distinguish mechanistic hypotheses |
| Regulatory status of XXB750 program | High | Program terminated by Novo Nordisk; no reformulation plan announced |
| FDA/EMA safety communications | High | No regulatory communications confirmed as of April 2026 |
| NT-proBNP trajectory in XXB750 arm | Medium | Would help characterize whether treatment was failing or causing active harm |
Relevant notes
- Guanylyl Cyclase — downstream pathway; vericiguat works here
- Heart Failure — HF background context
- NPR1 Agonists — drug class hub note